The management of multiple myeloma (MM) has evolved with the increased use of autologous haematopoietic cell transplantation (AHCT) and the introduction of new agents. AHCT and lenalidomide maintenance have been associated with increased risk of second primary malignancy (SPM). We iseutilised the Surveillance, Epidemiology and End Results 13 registries to analyse 9 833 patients diagnosed at age <65 years for three eras: 1995-99 (pre-thalidomide, limited use of AHCT), 2000-04 (post-thalidomide, pre-lenalidomide and bortezomib, increased isautilisation of AHCT) and 2005-09 (post-lenalidomide and bortezomib, higher isautilisation of AHCT). Changes in risk of SPM were assessed by utilising standardised incidence ratio (SIR) and cause-specific risk of death. Cumulative incidence of SPM at 90 months was 4Á7%, 6Á0% and 6Á3% respectively, P = 0Á0008. SIR for haematological malignancies in years 1-5 increased, from 1Á28 (95% confidence interval [CI] 0Á47-2Á78) in 1995-99 to 2Á17 (95% CI: 1Á27-3Á48) in 2005-09, due to increased risk of acute leukaemias and lymphomas. A similar trend was observed in years 6-10. Overall mortality in patients with MM declined sharply over time due to declines in MM-associated and cardiovascular mortality with no increase in risk of death from SPM. The evolution of MM therapy is linked to populationlevel increase in risk with no discernible effect in death from SPM.
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The management of patients with multiple myeloma (MM) has evolved significantly over the last two decades with the increased utilisation of high dose chemotherapy with autologous haematopoietic cell transplantation (AHCT) (Costa et al, 2013) , introduction of proteasome inhibitors (PIs) (Durie et al, 2017) and immunomodulatory agents (IMIDs) (Attal et al, 2012; McCarthy et al, 2012; Palumbo et al, 2012) and concomitant increase in survival, particularly among younger patients (Costa et al, 2017) . However, both AHCT (Fenk et al, 2012; Krishnan et al, 2013) and the IMID lenalidomide in maintenance have been associated with increased risk of second primary malignancy (SPM) in clinical trials and retrospective series, with the risk reaching 6Á9% at 5 years in a recent meta-analysis (Palumbo et al, 2014a) . Similarly, a recent and large series of MM patients who received AHCT had a 6Á1% incidence of SPM after 7 years (Mahindra et al, 2015) .
Although utilisation of AHCT has increased (Costa et al, 2013) along with a growing trend for the upfront use of lenalidomide in induction and maintenance regimens (Attal et al, 2012; McCarthy et al, 2012 McCarthy et al, , 2017 Palumbo et al, 2014b) , there has not been any population-based study demonstrating a change in risk of SPM or risk of death due to SPM in MM survivors. We assessed whether the evolution of myeloma therapy has affected the incidence of SPM or cause-specific mortality among patients diagnosed with MM in the US in the last two decades.
of AHCT, 10 years of follow-up) and 2005-09 (post-lenalidomide and bortezomib, highest utilisation of AHCT, 5 years of follow-up) with MM as first malignant neoplasm. Participating registries in SEER-13 are the Alaska Native, Atlanta, Connecticut, Detroit, Hawaii, Iowa, Los Angeles, New Mexico, San Francisco-Oakland, San Jose-Monterey, Rural Georgia, Seattle-Puget Sound and the Utah Tumor Registry, corresponding to approximately 13Á4% of the US population. Cancer registers included after 1995 (SEER-18) were not included to ensure the three cohorts contained data from the same registries. Follow-up is current to the end of 2014. We included patients younger than 65 years at the time of diagnosis of MM as the first malignant neoplasm to focus the analysis on patients more likely to receive AHCT and, presumably, prolonged lenalidomide exposure.
For each cohort, we calculated the incidence of SPM considering death from any cause as a competing risk. Given that comparison by era is subject to confounding by attained age, we analysed and compared standardised incidence ratios (SIRs) for SPM and causes of death in intervals of 5 years: years 1-5, years 6-10 and years 11-15 from diagnosis. To avoid confounding by concomitant diagnoses, we excluded SPM cases diagnosed within 6 months after diagnosis of MM. Consequently, the 6 months after MM diagnosis were not included in the "at risk" period and SPMs diagnosed during that period were not included. We also excluded non-melanoma skin cancer (NMSC) and myelodysplastic syndrome (MDS) from SPM events. NMSC has relatively low morbidity and is rarely fatal. As SEER only started capturing MDS in 2001, MDS was excluded from the definition of SPM to maintain consistency between the three cohorts.
Statistics
We utilised the case listing function of SEER*Stat 8.3.4 to obtain patient characteristics, including demographics, occurrence of subsequent malignancy, time and cause of death. We utilised the multiple primary SIR (MP-SIR) session to estimate the risk of development of another primary relative to age, gender, and race-matched general population. Individuals who developed one SPM were not excluded from risk of developing another SPM. Cause-specific risk of death was calculated per 1,000 patient*year at risk.
We compared continuous variables by group using the Kruskal-Wallis test for non-parametric data and rates using Z test. Death from any cause evidently precludes development of subsequent SPM and prolonged survival extends the period an individual is at risk for SPM. We therefore treated occurrence of "first" SPM as a time-to-event variable, reported and compared cumulative incidence considering death from any cause as a competing risk. We performed statistical analysis using SPSS (IBM Corp. Released 2013. IBM SPSS Statistics for Windows, Version 22.0. Armonk, NY). For competing risk analysis we utilised R v2.13.2 software using the "cmprsk package " (Scrucca et al, 2010) . Statistical tests were two-sided and considered significant when P < 0Á05.
Results
There were 2,720 patients in the 1995-99 cohort, 3 246 in the 2000-04 cohort and 3 867 in the 2005-09 cohort. Median age at diagnosis was 56 years and 56Á6% of the patients were males with no differences across cohorts (Table I) (Table I) . Cumulative incidences of SPM at 90 months were 4Á7% (95% CI: 4Á0-5Á6%), 6Á0% (95% CI: 5Á2-6Á8%) and 6Á3% (95% CI: 5Á5-7Á1%), respectively in the three consecutive cohorts, P = 0Á0008. The statistically significant, yet small increase in SPM was accompanied by decline in all-cause mortality in the same period from 69Á9% for the 1995-99 cohort to 60Á4% for the 2000-04 cohort to 52Á8% for the 2005-09 cohort, P < 0Á0001 (Fig 1) .
During years 1-5 after MM diagnosis, the risk of another cancer of any type evolved from lower than expected for patients diagnosed in 1995-99 (SIR = 0Á77, 95% CI: 0Á59-0Á99%) to similar to expected for patients diagnosed in 2005-09 (SIR = 1Á15, 95% CI: 0Á97-1Á36%), driven in part by an increase in haematological malignancies, from SIR = 1Á28 (95% CI: 0Á47-2Á78%) to SIR = 2Á17 (95% CI: 1Á27-3Á48%) (Fig 2) .
For years 6-10, the overall risk of subsequent malignancy in MM survivors is similar to the matched population for both the 1995-99 and the 2000-04 cohorts (most recent cohort with 10-year follow-up). However, the risk of subsequent haematological malignancy is increased in both periods. Remarkably, there was a substantial change in the risk of lymphomas between periods, evolving from SIR = 0Á59 (95% CI: 0Á01-3Á29%) for the 1995-99 cohort to SIR = 3Á31 (95% CI: 1Á51-6Á27%) for the 2000-04 cohort.
Complete follow-up for years 11-15 was available only for the 1995-99 cohort. There is an increased risk of haematological malignancy, driven mostly by increased risk of leukaemias, with no increase in the overall risk of second malignancies in comparison with general population (Fig 2) .
Cause-specific mortality
As expected, overall mortality in years 1-5 declined sharply over time (Table II) , driven by decline in both MM-related (from 159Á4 to 91Á7/1 000 patient-year) and cardiovascular mortality (from 12Á6 to 9Á1/1 000 patient-year). There was an increase in risk of death from infection over time, but no discernible increase in risk of death from SPM (from 4Á5 to 3Á9/1 000 patient-year). In years 6-10 there was also reduction in overall mortality, MM-related and cardiovascular mortality between the 1995-99 and the 2000-04 cohorts (Table II) .
Discussion
Treatment for MM has been associated with increased risk of SPM. This association was initially identified for alkylating agents (Govindarajan et al, 1996) , particularly melphalan (Cuzick et al, 1987) , including in the context of high dose chemotherapy and AHCT (Fenk et al, 2012; Krishnan et al, 2013) . In fact, Krishnan et al (2013) identified an 11Á2% risk of SPM (excluding NMSC) 10 years after AHCT for MM. Moreover, patients with clonal plasma cell disorders are at an intrinsically increased risk of MDS (Mailankody et al, 2011; Roeker et al, 2013) and acute myeloid leukaemia (AML) (Mailankody et al, 2011) , as documented in patients with monoclonal gammopathy of undetermined significance (MGUS) who did not receive myeloma therapy. A recent and large analysis from the Center for International Blood and Marrow Transplant Research (CIBMTR) with 4,161 MM recipients of AHCT identified a risk of SPM of 6Á1% at 7 years from transplant (Mahindra et al, 2015) .
More recently, the use of the immunomodulatory agent lenalidomide has also been linked with SPM, particularly when used in patients also exposed to alkylating agents (Usmani et al, 2013; Palumbo et al, 2014a; McCarthy et al, 2017) . A recent individual patient data meta-analysis of 3 254 patients in 9 trials identified the risk of SPM as being 6Á9% at 5 years in patients treated with lenalidomide versus 4Á8% in non-lenalidomide patients (Palumbo et al, 2014a) . Importantly, the increase in risk of SPM in lenalidomidetreated patients was driven mostly by an increase in risk of haematological malignancies (3Á1% vs. 1Á4%) (Palumbo et al, 2014a) . Another meta-analysis of randomised trials comparing lenalidomide versus placebo after AHCT also identified increased risk of SPM (both haematological malignancies and solid tumours) for lenalidomide-treated patients, although the increase in risk of SPM did not translate into higher risk of death from SPM (McCarthy et al, 2017) .
To this point, most data detailing the risk of SPM in MM patients derives from clinical trials, cohorts of selected patients or registry-based studies. While this approach allows more in-depth analysis of the effect of patient characteristics and treatment exposure on risk of SPM, it also has some limitations including the relatively small number of patients included, limited follow-up and the possibility that more intense therapy or more intense surveillance of those patients make findings less applicable to the general population.
A population-based analysis, such as the current one, benefits from larger number of patients and more extended follow-up to facilitate the identification of weaker associations as well as risks incidents with different latency from the exposure. It also has the potential to capture the effect of exposures beyond the first line of therapy. Also, given that MM affects predominantly elderly patients and cancer risk naturally increases with aging, the utilisation of SIR to factor in the expected incidence of malignancies in demographically similar population is crucial to discern the risks that are really linked to prior MM diagnosis (and presumably MM 
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Standardised incidence ratio of SPM in multiple myeloma survivors across 3 consecutive eras and with three latency periods. Diamonds indicate the SIR, and horizontal lines indicate the 95% CI for the SIR. CI, confidence interval; O, observed number of cases in the cohort during the period of observation; E, expected number of cases in a cohort with similar age, race/ethnicity and gender distribution in the same geographical area; SIR, standardised incidence ratio; SPM, second primary malignancy. therapy). Limitations to the present study include the fact that because systemic treatment information is not captured in SEER, the analysis by era of diagnosis makes only assumptions about treatment exposures. Given that all the individuals from an era are observed while only some of those individuals actually received the therapy suspected to increase the risk of SPM, this may lead to substantial underestimation of the impact of a given treatment on risk of SPM. Additionally, SEER does not distinguish between active MM requiring therapy and smouldering MM. This is the first US-based population-level study that identifies increased risk of SPM in MM patients. We confirmed that the evolution of MM therapy in the US in the last 20 years is associated with a small, statistically significant increase in the risk of SPM in patients aged <65 years independent of the longer survival associated with improvements in therapy. This increase is driven mostly by an increased incidence of haematological malignancies, confirming the observations made from clinical trial data sets (Palumbo et al, 2014a; McCarthy et al, 2017) . We found that this increase in risk of haematological malignancies has changed over time, coinciding with the broader utilisation of AHCT and introduction of lenalidomide. In this regard, it is remarkable that the risk of AML increases with longer follow-up of patients, but the magnitude of the increased risk appears similar between the three cohorts. Unique to this analysis is the identification of increased susceptibilities of MM patients to develop lymphomas. The increased risk is more evident in years 6-10 after diagnosis and is only noted in the 2000-04 and 2005-09 cohorts, suggesting a possible effect of lenalidomide exposure.
Of interest, the incidence of breast and prostate cancer were lower than expected in years 1-5 for the 1995-99 cohort, but subsequently increased to match the incidence in the general population for the 2005-09 cohort. The reason for such a trend is unknown, but we hypothesise that because incidences of prostate and breast cancers are largely driven by screening of asymptomatic individuals (Welch & Risk of death (per 1,000 patient-year) P
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Second cancers and survival in myeloma , 2009; Bleyer & Welch, 2012) , changes in the perception of MM from a rapidly fatal to a chronic treatable condition may have affected screening practices for patients with prior MM diagnosis.
One other large population-based study from Sweden reported on the incidence of SPM in MM survivors (Mailankody et al, 2011) .That study included all patients diagnosed with MM and MGUS in Sweden between 1986 and 2005 and found a SIR for SPM of 1Á26, with a SIR for haematological malignancies and AML/MDS of 2Á04 and 11Á51, respectively. Although that study did not find any significant difference in risk among patients diagnosed before and after the broader introduction of AHCT and lenalidomide, this may have been influenced by the shorter followup of patients exposed to these therapies.
The mechanism of increase in SPM among MM patients treated with lenalidomide remains elusive and potentially includes genetic susceptibility to develop malignancies. For MDS and AML, it is likely that exposure to alkylators lead to genetic alterations, including complex chromosome changes, monosomies and deletions that will subsequently manifest as clinically significant MDS or AML (Usmani et al, 2013; Palumbo et al, 2014a) . The mechanism of how lenalidomide enhances or accelerates this process is unknown. Similarly, there is no information on whether lenalidomide would increase the occurrence of lymphomas, making this a relevant question for future investigation.
The study also demonstrates that the mortality from SPM in MM survivors is modest and has not significantly increased over time. This finding is concordant with prior literature, including two meta-analysis that identified an increase in SPM with lenalidomide exposure but not in deaths caused by SPM (Palumbo et al, 2014a; McCarthy et al, 2017) . One possible reason for this finding is that many of the SPM detected in MM survivors are treatable and will not rapidly lead to death. More rapidly fatal SPMs, such as AML, although more frequent than in the general population, are still rare among MM survivors (Mailankody et al, 2011; Jonsdottir et al, 2016) . Importantly, the mortality from SPM associated with more contemporary therapy is obscured by the robust reduction in mortality from MM.
Apart from mortality from MM and SPM, we identified a reduction in the risk of cardiovascular deaths and increase in risk of death from infection in more recent years. Unfortunately, SEER-13 does not provide information on the specific types of fatal infection or the context where it occurred. It is likely that reduction in cardiovascular deaths is reflective of population trends and not related to MM diagnosis or therapy (Sidney et al, 2016) , but the reduced use of very high doses of corticosteroids (Rajkumar et al, 2010) and thalidomide and the establishment of thromboprophylaxis practices in MM patients may have influenced this trend (Palumbo, et al 2008) . The increase in risk of death from infection is intriguing and may reflect more intense therapy or even more accurate COD attribution of causes of death.
As therapy for MM continues to evolve and more patients enjoy the benefits of prolonged survival, the risk of SPM becomes more relevant. It is particularly concerning that prolongation of survival is being obtained partly by increased utilisation of AHCT and extended use of novel agents, including lenalidomide, two interventions known to increase risk of SPM. As the introduction of innovative therapies allows for achievement of early, deep and durable remissions in subsets of MM patients (Korde et al, 2015; Dimopoulos et al, 2016; Zimmerman et al, 2016; Attal et al, 2017) , future studies should focus on limiting the exposure to agents implicated in SPM and other morbidities.
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